194.37
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$196.39
Aprire:
$194.77
Volume 24 ore:
424.09K
Relative Volume:
0.31
Capitalizzazione di mercato:
$52.94B
Reddito:
$21.37B
Utile/perdita netta:
$1.41B
Rapporto P/E:
49.29
EPS:
3.9437
Flusso di cassa netto:
$3.07B
1 W Prestazione:
+0.29%
1M Prestazione:
+5.74%
6M Prestazione:
+29.39%
1 anno Prestazione:
+3.92%
Becton Dickinson Co Stock (BDX) Company Profile
Nome
Becton Dickinson Co
Settore
Industria
Telefono
(201) 847-6800
Indirizzo
ONE BECTON DR, FRANKLIN LAKES
Compare BDX vs ISRG, RMD, ALC, MDLN
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
BDX
Becton Dickinson Co
|
194.37 | 52.94B | 21.37B | 1.41B | 3.07B | 3.9437 |
|
ISRG
Intuitive Surgical Inc
|
444.41 | 157.00B | 11.03B | 3.16B | 3.22B | 8.7251 |
|
RMD
Resmed Inc
|
249.91 | 35.15B | 5.54B | 1.52B | 1.74B | 10.37 |
|
ALC
Alcon Inc
|
69.42 | 33.56B | 10.63B | 819.00M | 1.59B | 1.6577 |
|
MDLN
Medline Inc
|
33.05 | 28.99B | 29.14B | 1.07B | 1.05B | 1.1956 |
Becton Dickinson Co Stock (BDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-10-20 | Iniziato | Wolfe Research | Outperform |
| 2026-07-28 | Iniziato | UBS | Buy |
| 2026-05-04 | Ripresa | Evercore ISI | Outperform |
| 2026-04-10 | Ripresa | Goldman | Neutral |
| 2026-02-10 | Ripresa | Barclays | Overweight |
| 2026-02-03 | Ripresa | Citigroup | Buy |
| 2025-09-25 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2025-05-22 | Downgrade | Citigroup | Buy → Neutral |
| 2025-05-02 | Downgrade | Goldman | Buy → Neutral |
| 2025-05-02 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2025-05-02 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2025-05-01 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-05-01 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-01 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-10-01 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2023-07-24 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Overweight |
| 2023-05-05 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-04-12 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2023-01-03 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-12-12 | Aggiornamento | Citigroup | Sell → Neutral |
| 2022-07-11 | Downgrade | Citigroup | Neutral → Sell |
| 2022-06-24 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-03-18 | Ripresa | Raymond James | Mkt Perform |
| 2022-03-02 | Ripresa | BofA Securities | Neutral |
| 2021-12-08 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-08-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-05-25 | Iniziato | Barclays | Equal Weight |
| 2020-12-15 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-12-15 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-07-09 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2020-06-01 | Ripresa | Goldman | Buy |
| 2020-03-05 | Iniziato | Citigroup | Neutral |
| 2020-02-07 | Downgrade | Cowen | Outperform → Market Perform |
| 2020-02-07 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2020-02-07 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2020-02-06 | Downgrade | Cowen | Outperform → Market Perform |
| 2020-01-08 | Downgrade | Barclays | Overweight → Equal Weight |
| 2019-05-13 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2018-12-07 | Iniziato | Deutsche Bank | Buy |
| 2018-10-16 | Iniziato | Barclays | Equal Weight |
| 2018-06-21 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-04-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2018-01-19 | Ripresa | BofA/Merrill | Buy |
| 2018-01-05 | Aggiornamento | Citigroup | Sell → Neutral |
| 2018-01-05 | Iniziato | KeyBanc Capital Mkts | Overweight |
| 2018-01-03 | Iniziato | Evercore ISI | Outperform |
| 2017-12-29 | Reiterato | Deutsche Bank | Buy |
Mostra tutto
Becton Dickinson Co Borsa (BDX) Ultime notizie
DexCom Gears Up to Report Q3 Results: How to Play the Stock? - Zacks Investment Research
Will Baxter's Q3 Earnings Show Progress Despite Cost Pressures? - Zacks Investment Research
Becton Dickinson appoints Ferass Abuzaina as worldwide president of Surgery - scanx.trade
ResMed Set to Report Q1 Earnings: What's in the Cards for the Stock? - Zacks Investment Research
BECTON, DICKINSON AND COMPANY (4BDX.TI) latest stock news and headlines - Yahoo Finance Australia
Becton Dickinson & Co (BDX) Shares Surge 3.1% -- What GF Score o - GuruFocus
Becton Dickinson & Co. stock outperforms competitors on strong trading day - MarketWatch
BDX Stock Gains 25.5% in Six Months: What's Behind the Rally? - Zacks Investment Research
Becton Dickinson stock hits 52-week high at 196.42 USD - Investing.com
Becton Dickinson stock hits 52-week high at 196.42 USD By Investing.com - Investing.com Canada
BDX.GJ Bond Profile: Coupon and Redemption - TradingView
DHR Q3 Earnings Beat on Biotechnology Strength, Sales in Line - Zacks Investment Research
Catholic Medical Mission Board and Church of the Brethren to mark partnership with ribbon-cutting - GlobeNewswire Inc.
Becton, Dickinson: Fundamentals Remain Solid, Trades Near Fair Value (Rating Downgrade) - Seeking Alpha
31,495 Becton, Dickinson and Company $BDX Shares Sold by Forbes J M & Co. LLP - InsuranceNewsNet
XS2839004368 Bond Yield and Price — BONDSCOM:XS2839004368 - TradingView
Becton, Dickinson and Co (BOX.MU) stock price, news, quote and history - Yahoo Finance UK
Becton Dickinson & Co. stock outperforms competitors despite losses on the day - MarketWatch
Becton Dickinson & Co. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
BD's Revello Stent Shows Strong AGILITY Trial Results for PAD Patients - Zacks Investment Research
Becton Dickinson stock hits 52-week high at 193.1 USD - Investing.com
Global Microbiology Testing Market to Grow Rapidly at a CAGR of ~9% by 2034 | DelveInsight - GlobeNewswire Inc.
Becton, Dickinson and Company Yields 2.4%: Is Its Valuation Finally Worth a Look? - Yahoo Finance
Becton Dickinson (BDX) Grew Revenue 5.4% While Earnings Fell 34.3%. Why Did Profit Fall So Much Further? - Yahoo Finance
Becton Dickinson & Co. stock outperforms competitors on strong trading day - MarketWatch
Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report? - Zacks Investment Research
News | Medical-supply maker BD pledges $19 billion investment in US operations - CoStar
Becton Dickinson & Co. stock outperforms competitors on strong trading day - MarketWatch
Celebrating a medical milestone - Plastics News
BD strikes $19B manufacturing deal with US government - NJBIZ
Barclays Initiates Coverage on Becton, Dickinson and Company With Underweight Rating, $165 Price Target - Moomoo
BDX Expands U.S. Manufacturing With $19B Healthcare Investment - Zacks Investment Research
Becton, Dickinson and Company (BDX) Stock Forecast and Price Target 2026 $BDX - MarketBeat
Barclays Initiates Coverage on Becton, Dickinson and Company With Underweight Rating, $165 Price Target - Yahoo Finance
Becton Dickinson pledges $19 billion US investment in deal with government - Reuters
Becton Dickinson to Spend $3 Billion Expanding US Medical Manufacturing, Trump Says - BigGo Finance
BD to invest billions in U.S. manufacturing - Medical Design & Outsourcing
Becton Dickinson Commits Massive $19 Billion To Expand Domestic Medical Manufacturing - Benzinga
BD to invest $19B in the US to bring relief from future tariffs - BioWorld News
Trump says Becton Dickinson to invest $3 billion in US medical manufacturing By Investing.com - Investing.com
Becton Dickinson to Invest $19 Billion in U.S. in Exchange for Tariff Relief - WSJ
BD Appoints Ferass Abuzaina as Worldwide President of Surgery – Company Announcement - Financial Times
A new leader takes charge of BD’s Surgery business immediately - Stock Titan
Becton Dickinson to invest $19 billion in US - Yahoo Finance
BD and U.S. Government Launch Landmark Partnership to Expand U.S. Manufacturing and Strengthen America's Healthcare Resilience – Company AnnouncementFT.com - Financial Times
Trump Says Becton Dickinson to Invest $3 Billion in US Manufacturing as 'Strong' Medical Device Tariffs L - Benzinga
Trump Says Becton Dickinson to Invest $3 Billion in US Manufacturing as 'Strong' Medical Device Tariffs Loom by Year-End - TradingView
Trump Says Becton Dickinson to Invest $3 Billion to Expand Medical Product Manufacturing - NTD News
Becton Dickinson (BDX) to Invest $3 Billion in U.S. Medical Supp - GuruFocus
Trump says Becton Dickinson to invest $3 billion in US medical manufacturing - Yahoo Finance
Becton Dickinson Co Azioni (BDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Becton Dickinson Co Azioni (BDX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| MICHAEL FELD | Officer |
Sep 28 '26 |
Proposed Sale |
183.82 |
76 |
13,970 |
0 |
| Feld Michael | EVP, Chief Revenue Officer |
Sep 28 '26 |
Sale |
183.70 |
76 |
13,961 |
19,644 |
| Feld Michael | EVP, Chief Revenue Officer |
Aug 26 '26 |
Sale |
188.49 |
165 |
31,101 |
19,720 |
| MICHAEL FELD | Officer |
Aug 26 '26 |
Proposed Sale |
189.78 |
165 |
31,314 |
0 |
| RICHARD BYRD | Former Officer |
Aug 20 '26 |
Proposed Sale |
187.97 |
1,330 |
249,993 |
0 |
| THOMAS POLEN | Director |
Aug 13 '26 |
Proposed Sale |
183.58 |
4,152 |
762,224 |
0 |
| Polen Thomas E Jr | Chairman, CEO and President |
Aug 13 '26 |
Option Exercise |
167.25 |
43,278 |
7,238,246 |
153,441 |
| Polen Thomas E Jr | Chairman, CEO and President |
Aug 13 '26 |
Sale |
185.00 |
4,152 |
768,120 |
110,163 |
| Roland Goette | Officer |
Aug 11 '26 |
Proposed Sale |
180.84 |
2,438 |
440,877 |
0 |
| Goette Roland | EVP and President, EMEA |
Aug 11 '26 |
Sale |
180.84 |
2,438 |
440,888 |
14,856 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):